Investors Urged to Act Against Unicycive Therapeutics Class Action Lawsuit

Overview of the Case
On October 1, 2025, Levi & Korsinsky, LLP informed investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) about a significant class action lawsuit aimed at recovering losses for those who faced adverse effects due to alleged securities fraud. This lawsuit targets individuals who invested in Unicycive between March 29, 2024, and June 27, 2025.

The complaint alleges that the company, Unicycive Therapeutics, overstated its compliance with FDA manufacturing requirements and misled shareholders regarding the regulatory prospects for its oxylanthanum carbonate new drug application. As such, public statements from Unicycive were materially false and misleading, potentially leading to significant financial losses among investors.

Important Details for Investors

Investors who suffered losses during the relevant period are urged to act swiftly, as they have until October 14, 2025 to request the Court to appoint them as lead plaintiff. This is a crucial step for anyone wanting to take a more substantial role in the class action. However, it’s worth noting that not serving as a lead plaintiff does not prevent anyone from sharing in any potential recovery from the case.

No Costs Involved

For individuals who qualify as class members, there are no out-of-pocket costs to participate in the lawsuit. Levi & Korsinsky has made it clear that investors can file claims without incurring additional fees or obligations, making this a financially viable option for those affected.

Why Choose Levi & Korsinsky?

With a track record of winning high-stakes cases over the past two decades, Levi & Korsinsky has successfully secured hundreds of millions for disgruntled shareholders. The firm boasts a dedicated team of over 70 professionals experienced in navigating complex securities litigation. Additionally, Levi & Korsinsky has been consistently recognized in ISS Securities Class Action Services' Top 50 Report over the last seven years for its excellence in the field.

Next Steps for Investors

Affected investors can use the link provided on Levi & Korsinsky's website to acquire more information on the lawsuit and to get in touch with their team. Alternatively, investors are welcome to contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

The law firm emphasizes the importance of acting promptly to ensure participation in potential reparations. This might not only include financial compensation but also serve as a reminder to companies regarding the importance of transparency with their investors.

Conclusion

In light of the ongoing class action, investors in Unicycive Therapeutics have a timely opportunity to protect their interests and seek justice for any alleged misrepresentation by the company. Amid the current market landscape, vigilance and proactive engagement with legal proceedings are vital for those impacted.

For continuous updates and assistance, keep an eye on communications from Levi & Korsinsky as the case evolves.